By

Published on

November 20, 201810:10 EST

The group of Takeda minority shareholders known as Thinking about Takeda’s Bright Future (TTBF) is focusing all its efforts on talking to domestic institutions such as life insurance companies into voting against the acquisition of Shire featured

By

Published on

November 14, 201810:39 EST

On October 26 Takeda announced it had proposed a remedy to the European Commission of selling Shire’s SHP647, a pipeline compound for the treatment of inflammatory bowel disease, which will potentially compete with Takeda’s marketedfeatured

By

Published on

October 18, 201809:45 EST

Takeda expects to hear from the European Commission by the end of the week regarding potential concerns the commission might have with Takeda’s acquisition of Shire, a source close to the situation told CTFN.featured

By

Published on

October 1, 201813:03 EST

Chances that the group of Takeda minority shareholders opposing the Japanese drug maker’s planned acquisition of rival Shire will succeed in blocking the deal appear to be low, local sources told CTFN.featured

By

Published on

September 28, 201810:50 EST

Updated at 12:25pm While CTFN originally expected Takeda to miss the end of September deadline for its EC filing by a few days, Takeda today filed with the EC its merger with Shire with a provisional deadline of November 6, 2018.featured

By

Published on

April 27, 201814:20 EST

Japanese pharmaceutical player Takeda should not face issues securing funds for a potential deal with Dublin-headquartered peer Shire, a Tokyo-based M&A lawyer who in the past advised targets acquired by Takeda, told CTFN.featured